EPHA2 and breast carcinoma: This hypothesis is supported by our in vivo studies showing the efficacy of molecular/genetic and pharmacologic inhibition of EphA2 in reducing osteolytic disease in breast cancer bone allograft and xenograft experimental metastasis models.